-Advertisement-
-Advertisement-
Trending Topics
No increased risk of cardiorenal outcomes seen after anti-VEGF therapy in eye disease
To determine the risk of developing cardiorenal side effects due to the systemic absorption of intravitreal injections of vascular endothelial growth factor inhibitors (anti-VEGF) therapies, researchers analyzed randomized controlled trials of intravitreal bevacizumab, ranibizumab, and aflibercept for the treatment of any eye disease. Overall, the incidence of hypertension, heart failure,...
Read More-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
Contact Info
© 2024 Ophthalmology 360® is a trademark of International Healthcare Media, LLC. All rights Reserved